Erratum to: Infect Dis Ther (2016) DOI 10.1007/s40121-016-0119-9
Following publication of the aforementioned article, the authors noted a minor error in Table 1 and two small errors in Table 2. In Table 1, the Eron Class III Clinical Criteria should read CrCl <30 mL/min or on dialysis, not CrCl <20 mL/min. In Table 2, Distribution of SOLO patients in modified Eron Classes I–III, the number of outpatients receiving vancomycin (VAN) in Class I should be 111, not 11. The total number of inpatients (Class I–III) was omitted, n = 1143 (59.8%).
Table 1.
Clinical criteria used to define modified Eron Classes I–IV
| Eron class | Clinical criteria |
|---|---|
| IV |
Bacteremia (positive blood culture); or Absolute total neutrophils count <500 |
| III |
Meeting SIRS criteria CrCl <30 mL/min or on dialysis ALT/AST >10-times ULN Heart rate >90/min, breath rate >20/min, or systolic BP <90 mmHg; or Cancer |
| II |
Age ≥75 years old Glucose >11.1 mmol/L Congestive heart failure at the randomization 30 mL/min < CrCl <60 mL/min Hepatitis (excluding AST/ALT >10-times ULN) Peripheral vascular disease Diabetes mellitus Fever (temperature >38.0 °C); or BMI ≥30 kg/m2 |
| I | For the patients who didn’t meet Classes II–IV |
ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, BP blood pressure, CrCl creatinine clearance, SIRS systemic inflammatory response syndrome, ULN upper limit of normal
Table 2.
Distribution of SOLO patients in modified Eron Classes I–III (mITT population, n = 1959)
| Class I | Class II | Class III | Total (Class I–III) | |
|---|---|---|---|---|
| SOLO mITT (n = 1959) | 520 (26.5%) | 790 (40.3%) | 600 (30.6%) | 1910 |
| Inpatients, n (%) | 301 (57.9%) | 431 (54.6%) | 411 (68.5%) | 1143 (59.8%) |
| ORI, n | 144 | 224 | 203 | 571 |
| VAN, n | 157 | 207 | 208 | 572 |
| Outpatients, n (%) | 219 (42.1%) | 359 (45.4%) | 189 (31.5%) | 767 (40.2%) |
| ORI, n | 108 | 182 | 89 | 379 |
| VAN, n | 111 | 177 | 100 | 388 |
mITT modified intent-to-treat, ORI oritavancin, VAN vancomycin
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Footnotes
The online version of the original article can be found under doi:10.1007/s40121-016-0119-9.
Contributor Information
Daniel H. Deck, Email: Daniel.Deck@THEMEDCO.com
Jennifer M. Jordan, Email: Jennifer.jordan@themedco.com